Migraines

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti- Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing vasoconstriction.

More: continued here